Kelun Pharmaceutical secures RMB 500m in innovation bonds

Sichuan Kelun Pharmaceutical Company Limited announced the successful issuance of its 2025 second tranche of science and technology innovation bonds, raising RMB 500 million. The bonds, with a simplified name of "25科伦 SCP002 (科创债)", were issued on September 11, 2025, with proceeds fully received on September 12, 2025. This issuance falls under the company's approved debt financing tools, which were authorized by the board of directors on April 12, 2023, and by shareholders on May 4, 2023.

The unsecured short-term financing bonds carry a term of 270 days, with an interest rate of 1.58% and a par value of 100 RMB per 100 RMB. The maturity date is June 9, 2026. The company holds an AAA/AAAsti credit rating, as confirmed by its primary underwriters, including Industrial Bank Co., Ltd., Bank of Chengdu Co., Ltd., China Minsheng Banking Corp., Ltd., and China CITIC Bank Co., Ltd.

The funds raised from this bond issuance are designated for repaying existing liabilities and supplementing working capital. The company affirmed that it is not a defaulting entity as of the announcement date.